Search Results 101-110 of 9838 for Nuedexta

  1. A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis - Mayo Clinic

    If taking riluzole and/or Nuedexta®, stable regimen is required for ≥ 30 days prior to screening. Medically (either independently or with caregiver ...

  2. Cancer Treatment! Clinical Trials - Mayo Clinic Research

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 in ...

  3. Phase I Study of LB-100 With Docetaxel in Solid Tumors - Mayo Clinic

    LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs approved to treat some types of ...

  4. Drugs and Supplements that Start with P - Mayo Clinic

    Drugs and Supplements · P P & S Also known as. Salicylic acid (topical route) · Pa. Pacaps. Also known as. Butalbital, acetaminophen, and caffeine (oral route).

  5. A Study To Evaluate The Safety, Tolerability, And Effects On Blood And Urine Markers Of Single Ascending Dose Of GSK4771261 In Healthy Participants And Participants With Autosomal Dominant Polycystic Kidney Disease - Mayo Clinic

    This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is ...

  6. Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas - Mayo Clinic

    Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas · More about research at Mayo Clinic.

  7. https://www.mayoclinic.org/arabic_patient_consumer_video.xml

  8. https://www.mayoclinic.org/arabic_condition_consolidated_concepts.xml

  9. https://www.mayoclinic.org/arabic_patient_consumer_faq.xml

  10. SC16LD6.5 in Recurrent Small Cell Lung Cancer - Mayo Clinic

    5 will be assessed by measuring the extent of tumor shrinkage. SC16LD6.5 is an antibody-drug conjugate (ADC). The antibody (SC16) targets a protein that appears ...